Moderna’s newest vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration.
Moderna’s newest Covid vaccine generated a robust immune response against the now-dominant Eris variant and another rapidly spreading strain of the virus in an early clinical trial, the biotech company recently stated. The updated shot is designed to target omicron subvariant XBB.1.5, but the results suggest that the injection may still be effective against newer variants of the virus that are gaining ground nationwide. That includes Eris and another variant nicknamed Fornax, both of which are also descendants of the omicron virus variant.
Read the full article at: www.cnbc.com